DKDavid J. Karras

David J. Karras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David J. Karras has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Urine Dipstick as a Screening Test for Serum Creatinine Elevation in Emergency Department Patients with Severe Hypertension

    by David J. Karras, Katherine L. Heilpern, Louis J. Riley, Lynn Hughes, John P. Gaughan

    Patients presenting to the emergency department (ED) with severe hypertension require assessment for acute end-organ damage. Serum creatinine (SCr) measurement is routinely recommended to detect renal dysfunction. The authors assessed the utility of the urine dipstick test in screening for acute SCr elevation in this population. The authors performed a prospective study of adult ED patients with diastolic blood pressures > or = 115 mm Hg that persisted for > or = 30 minutes or necessitated emergent treatment. Excluded were menstruating and pregnant women and patients with urinary infection, trauma, or dialysis dependence. Patients reporting a history of renal disease were excluded if the SCr was abnormal and no baseline value was available. Each subject had an SCr and urine dipstick test. The authors examined the performance of the dipstick in identifying an elevated SCr, defined as SCr > 1.2 mg/dL or > 25% above baseline. Of 143 patients, 42 had SCr > 1.2 mg/dL. Eighteen reported prior renal disease but had an SCr that was normal or < or = 25% above baseline. The remaining 24 subjects comprised the elevated SCr group. The presence of either proteinuria or hematuria on dipstick identified these patients with 100% sensitivity and 29.7% specificity. Specificity rose to 42.4% without loss of sensitivity when an abnormal dipstick was defined as hematuria or > or = 1+ proteinuria. The urine dipstick may be an effective screening test for SCr elevation in patients with severe hypertension. A restrictive definition of an abnormal dipstick would identify all patients with elevated SCr and substantially reduce the number of SCr assays necessary.


  • Open Access

    Clinically Meaningful Changes in Quantitative Measures of Asthma Severity

    by David J. Karras, Maura E. Sammon, Carol A. Terregino, Bernard L. Lopez, Sharon K. Griswold, Gerald K. Arnold

    Objective: To determine minimum clinically meaningful improvements in peak expiratory flow rate (PEFR) and dyspnea visual analog score (VAS) in patients with acute asthma exacerbation. Methods: Patients presenting to the emergency department (ED) with acute asthma exacerbation were eligible. The PEFR and VAS were assessed at presentation and after initial asthma therapy. During reassessment, subjects were asked to describe their asthma symptoms as “much better,”“a little better,”“no change,”“a little worse,” or “much worse.” Correspondence between self‐reported improvement and changes in PEFR and VAS was assessed. The “minimum clinically significant change” in either index was defined as the difference between pre‐ and post‐treatment measures in subjects reporting their symptoms “a little better.” Results: One hundred fifty‐six subjects were included. Asthma symptoms were “much better” in 99 (64%), “a little better” in 41 (26%), and “unimproved” (composed of patients describing symptoms as “no change,”“a little worse,” or “much worse”) in 16 (10%). The mean VAS change among the “a little better” subjects was 2.2 cm (95% CI = 1.1 to 3.4), significantly greater than the ‐0.4 cm (95% CI = ‐2.1 to 1.4) change in the “unimproved” subjects. The mean change in percent predicted PEFR among the “a little better” subjects was 11.9 (95% CI = 7.3 to 16.1), not statistically different from the change of 6.1 (95% CI = 1.1 to 11.3) in the “no change” subjects. The “much better” group showed significantly greater changes in both measures than either of the other groups. A VAS change of ≥0.5 cm reliably discriminated between subjects with and without symptom improvement. Conclusions: Improvements in VAS of 2.2 cm and in predicted PEFR of about 12 percentage points are minimal clinically significant improvements during ED asthma therapy. The dyspnea VAS is valid in assessing symptomatic changes and may detect small subjective improvements better than the PEFR.